Tag: Bristol-Myers Squibb
NATCO Pharma launches lenalidomide 2.5mg and 20mg in US
NATCO Pharma said that it has launched additional strengths for the generic version of Revlimid (lenalidomide capsules), in the strengths of 2.5mg and 20mg in ... Read More
Bristol Myers Squibb gets Reblozyl EC approval for anemia associated with NTD beta thalassemia
Bristol Myers Squibb (BMY) has secured full marketing authorization for Reblozyl (luspatercept) from the European Commission (EC) for treating anemia associated with non-transfusion-dependent (NTD) beta ... Read More
Viz.ai, Bristol Myers Squibb sign deal for AI algorithm and Viz HCM software
Viz.ai, an artificial intelligence (AI) powered health technology company, has signed a multi-year agreement with Bristol Myers Squibb (BMY) to provide the latter with an ... Read More
BMS to acquire precision oncology company Turning Point Therapeutics for $4.1bn
Bristol Myers Squibb (BMS) has agreed to acquire Turning Point Therapeutics, a clinical-stage precision oncology company based in California, for $4.1 billion. Listed on the ... Read More
Alembic Pharmaceuticals gets FDA approval for Dasatinib Tablets
Alembic Pharmaceuticals has secured tentative approval for the abbreviated new drug application (ANDA) of Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 ... Read More
Bristol Myers Squibb gets FDA priority review for Breyanzi sBLA
Bristol Myers Squibb (BMS) has secured priority review from the US Food and Drug Administration (FDA) for its supplemental biologics license application (sBLA) for Breyanzi ... Read More
Sun Pharma to settle patent litigation with Celgene for generic Revlimid
Sun Pharmaceutical Industries (Sun Pharma) along with one of its fully-owned subsidiaries has reached an agreement with Celgene, a fully-owned subsidiary of Bristol Myers Squibb, ... Read More
Natco Pharma gets FDA approval for Lenalidomide Capsules
Natco Pharma has secured the final approval from the US Food and Drug Administration (FDA) of its abbreviated new drug application (ANDA) for Lenalidomide Capsules, ... Read More
BMS, bluebird bio bag Abecma FDA approval for multiple myeloma in adults
Abecma FDA approval : Bristol Myers Squibb (BMS) and bluebird bio have secured approval from the US Food and Drug Administration (FDA) for Abecma (idecabtagene ... Read More
BMS gets Opdivo EC approval for second-line treatment of ESCC
Opdivo EC approval : Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for its immunotherapy Opdivo (nivolumab) as a second-line treatment ... Read More